Jason Lee, MD
Allergy & Immunology · West Hartford, CTNPI 1760463400
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.8%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Pharming Healthcare, Inc. at 52.5% of the total. 2025 is the largest year on record at $11,942, more than ten times the $391 reported in 2019. Among allergy & immunology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 235 payments — averaging $129.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharming Healthcare, Inc.$16K
- CSL Behring$8K
- GSK$2K
- AstraZeneca$1K
- Sanofi$572
- LEO Pharma Inc.$510
- plus $3K from 18 others
What the payments were for
- Consulting fees$13,33144%
- Speaking & faculty fees$5,50018%
- Travel & lodging$4,55615%
- Food & beverage$7,01623%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharming Healthcare, Inc. | 31 | $15,956 |
| CSL Behring | 17 | $8,075 |
| GSK | 80 | $1,610 |
| AstraZeneca | 25 | $1,151 |
| Sanofi | 5 | $572 |
| LEO Pharma Inc. | 11 | $510 |
| Eyevance Pharmaceuticals LLC | 1 | $500 |
| Regeneron Healthcare Solutions, Inc. | 5 | $411 |
| Novartis | 20 | $287 |
| Lilly USA, LLC | 7 | $250 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $171 |
| Grifols USA, LLC | 6 | $163 |
| GE HealthCare | 1 | $123 |
| Boston Scientific | 1 | $113 |
| Genentech USA, Inc. | 4 | $94 |
| Biocryst US Sales Co., LLC | 2 | $90 |
| Merck | 1 | $75 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $71 |
| GC Biopharma USA, Inc. | 2 | $51 |
| Verona Pharma, Inc. | 2 | $37 |
| Ionis Pharmaceuticals, Inc. | 1 | $35 |
| AbbVie | 1 | $28 |
| Vericel Corporation | 1 | $27 |
| Organon | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,403 in reported general payments places this provider in the 90th percentile of 54 allergy & immunology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 51 | $141,351 |
| Dupixent SyringeDupilumab | 35 | $138,063 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $85,107 |
| TezspireTezepelumab-Ekko | 19 | $83,558 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 20 | $77,732 |
| Dupixent PenDupilumab | 18 | $65,264 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $31,902 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 72 | $23,636 |
| DuleraMometasone/Formoterol | 33 | $22,394 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $22,028 |
| SymbicortBudesonide/Formoterol Fumarate | 48 | $19,273 |
| Cyclosporine | 13 | $15,485 |
| Spiriva RespimatTiotropium Bromide | 12 | $11,621 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 78 | $9,647 |
| Epinephrine | 33 | $8,993 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $1,151 | $134,733100 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,610 | $107,13497 claims |
| CSL BehringHizentra | $8,075 | $77,73220 claims |
| MerckDulera | $75 | $22,39433 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 54 allergy & immunology providers in Connecticut.
Other allergy & immunology in West Hartford
- Gavin SchwarzWest Hartford$262K
- Wei AnWest Hartford$4K
- Shamsa ShafiWest Hartford$2K
- Leonard CohenWest Hartford$62
- Christina PriceNew Haven$96K
- Florence HsuNorth Haven$84K
- Birur ChandraEast Haven$15K
- Michael KingTrumbull$14K
- Prasad SrinivasanGlastonbury$14K
- Anita Kohli-PamnaniOrange$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.